先天性巨细胞病毒感染新生儿期后治疗的单臂Meta分析
本研究通过单臂Meta分析评估新生儿期后先天性巨细胞病毒感染抗病毒治疗的听力结局,纳入8项研究共192例患者。口服缬更昔洛韦与治疗前2个月病毒载量下降相关,听力损失耳中42.29%恢复正常、38.48%改善,听力恶化仅5.47%,中性粒细胞减少发生率低,但长期结局尚不明确。
要点
- 新生儿期后口服缬更昔洛韦可降低尿和血浆病毒载量。
- 听力损失耳中约42%恢复正常、38%改善,恶化少见。
- 中性粒细胞减少发生率低,3-4级仅3.67%。
核心结论
- 新生儿期后抗病毒治疗可能降低病毒载量并改善相当比例患者的听力,不良事件发生率低。
- 长期结局仍不明确,需更大规模前瞻性研究确认疗效。
研究设计与样本
- 单臂Meta分析,系统检索PubMed、Embase、Web of Science和Cochrane Library。
- 纳入8项报告新生儿期后使用更昔洛韦或缬更昔洛韦治疗先天性巨细胞病毒感染的研究,共192例患者。
主要发现
- 口服缬更昔洛韦与治疗前2个月病毒载量下降相关。
- 2个月时尿病毒载量合并均数差为-3.67(95%CI -4.33至-3.02,I2=75.4%)。
- 2个月时血浆病毒载量合并均数差为-0.80(95%CI -1.08至-0.52,I2=31.6%)。
- 听力损失耳中恢复正常占42.29%(95%CI 13.48至77.51,I2=84.3%),改善占38.48%(95%CI 16.77至66.00,I2=88.2%)。
- 听力恶化占总耳数5.47%(95%CI 2.15至13.25,I2=60.9%),中性粒细胞减少1-2级占9.09%、3-4级占3.67%。
临床怎么用
- 对新生儿期后先天性巨细胞病毒感染伴听力损失者,可考虑口服缬更昔洛韦治疗并监测病毒载量。
- 治疗期间需监测中性粒细胞减少等不良事件。
- 应告知患者长期听力结局尚不明确,需长期随访。
局限性
- 单臂Meta分析,缺乏对照组。
- 纳入研究数量少(8项)且样本量有限(192例)。
- 长期结局不明确。
- 部分结局异质性较高(如听力恢复正常I2=84.3%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate hearing outcomes in postneonatal treatment of congenital cytomegalovirus (cCMV) infection and assess the effect of treatment initiated after the first month of life. DATA SOURCES: PubMed, Embase, Web of Science, and Cochrane Library were systematically searched. REVIEW METHODS: Articles reporting antiviral treatment of cCMV, with Ganciclovir (GCV) or Valganciclovir (VGCV) in the postneonatal period were included. Outcomes of interest included viral load (urine and plasma), neutropenia, and hearing outcomes (return to normal hearing, improvement, deterioration, and no change). Mean difference (MD) was used for continuous outcomes and proportions for binary endpoints, with 95% confidence intervals (CI). RESULTS: Eight studies with 192 patients met inclusion criteria. Oral VGCV was associated with a reduction in viral load during the first 2 months. At 2 months, pooled MD for urine viral load was -3.67 (95% CI -4.33 to -3.02, I2 = 75.4%), and for plasma was -0.80 (95% CI -1.08 to -0.52, I2 = 31.6%). Among patients with hearing loss, normalization occurred in 42.29% (95% CI 13.48 to 77.51, I2 = 84.3%) and improvement in 38.48% (95% CI 16.77 to 66.00, I2 = 88.2%) of total ears. Hearing deterioration was uncommon, affecting 5.47% of total ears (95% CI 2.15 to 13.25, I2 = 60.9%). Neutropenia was infrequent, with 9.09% experiencing grade 1-2 and 3.67% grade 3-4. CONCLUSION: Postneonatal antiviral treatment for cCMV may reduce viral load and improve hearing in a substantial proportion of patients, with low rates of adverse events. However, long-term outcomes remain unclear, and larger prospective studies are needed to confirm efficacy. LEVEL OF EVIDENCE: N/A.
引用
- Cabral TDD, Mafra M, Plane J, et al. Treatment of Congenital Cytomegalovirus Beyond the Neonatal Period: A Single-Arm Meta-Analysis. Laryngoscope. 2026. PMID: 42682177. doi:10.1002/lary.70833
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。